Search

Your search keyword '"Ascierto P"' showing total 756 results

Search Constraints

Start Over You searched for: Author "Ascierto P" Remove constraint Author: "Ascierto P"
756 results on '"Ascierto P"'

Search Results

151. Outcomes in patients with BRAFV600–mutated melanoma and brain metastases at baseline treated with dabrafenib plus trametinib

153. Staging and prognostic factors

154. Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial (Journal of Translational Medicine, (2020), 18, 1, (405), 10.1186/s12967-020-02573-9)

155. 42TiP A multicenter, randomized, double-blind phase III study of HBI-8000 combined with nivolumab versus placebo with nivolumab in patients with unresectable or metastatic melanoma not previously treated with PD-1 or PD-L1 inhibitors

158. The surgical treatment of non-metastatic melanoma in a Clinical National Melanoma Registry Study Group (CNMR): a retrospective cohort quality improvement study to reduce the morbidity rates

159. Nivolumab vs placebo dans le traitement adjuvant des patients atteints d’un mélanome de stade IIB/C : résultats à 3 ans de l’étude CheckMate 76K (CM 76K)

160. Efficacité et tolérance de nivolumab + relatlimab (NIVO+RELA) versus nivolumab + ipilimuab (NIVO+IPI), dans le traitement de première ligne (1L) du mélanome avancé : données actualisées d’une comparaison indirecte de traitement

161. Encorafénib plus binimétinib suivi d’ipilimumab plus nivolumab versus ipilimumab plus nivolumab chez des patients atteints de mélanome avancé muté BRAF-V600E/K : résultats de l’étude de phase II de l’EORTC (EBIN)

162. Étude de phase 3 (PIVOTAL) sur le daromun intralésionnel néoadjuvant comparé à une chirurgie immédiate dans le mélanome entièrement résécable avec métastases cutanées régionales et/ou ganglionnaires

163. Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO dans le mélanome non préalablement traité, métastatique ou non résécable (RELATIVITY-047) : résultats de survie globale (OS) et de survie spécifique au mélanome (MSS) à 3ans

166. The need for a network to establish and validate predictive biomarkers in cancer immunotherapy

167. First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers

168. Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment

169. Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment

170. Corrigendum: “Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma” (European Journal of Cancer (2021) 157 (250–258), (S0959804921005360), (10.1016/j.ejca.2021.08.018))

171. Metastatic endo and perineural involvement of the ulnar nerve from malignant melanoma: ultrasound (US) and magnetic resonance imaging (MRI) findings

173. Nationwide multidisciplinary consensus on the clinical management of Merkel cell carcinoma: a Delphi panel

175. Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma

176. Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases

178. Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial.

179. Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma.

180. Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial

181. The Clinical and Translational Research Activities at the INT – IRCCS 'Fondazione Pascale' Cancer Center (Naples, Italy) during the COVID-19 Pandemic

184. Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study

185. Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915).

186. Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF -Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial.

187. COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600–Mutant Melanoma.

190. Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO dans le mélanome métastatique ou non résécable précédemment non traité : résultats à 2 ans de RELATIVITY-047

191. 1084P PLATForM: Descriptive analysis from a randomised, phase II study of novel spartalizumab combinations in previously treated unresectable/metastatic melanoma

192. Role of the androgen receptor in melanoma aggressiveness

198. A first-in-human trial on the safety and immunogenicity of COVID-eVax, a cellular response-skewed DNA vaccine against COVID-19

Catalog

Books, media, physical & digital resources